Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Modulight

1.23

 

EUR

 

0 %

2,768 following

MODU

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Compare
0%
+6.59%
-2.69%
+16.04%
+28.13%
+11.82%
-71.13%
-
-88.76%

Modulight operates in the technology industry. The company designs, markets, and produces biomedical laser products used in oncology, genetics, and ophthalmology. The customers primarily consist of hospitals and corporate customers operating in medical technology. In addition to the main business, various value-added services are also offered. Their main market is the US.

Read more
Market cap
52.42M EUR
Turnover
67.7K EUR
P/E (adj.) (25e)
-9.79
EV/EBIT (adj.) (25e)
-8.08
EV/S (25e)
5.85
Dividend yield-% (25e)
-
Coverage
Recommendation
Accumulate
Target price
1.50 EUR
Updated
01.07.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 01.07.2025

Latest extensive report

Released: 01.07.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
22.8
2025

Interim report Q2'25

24.10
2025

Interim report Q3'25

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Modulight extensive report: Building a new growth base
Extensive research7/1/2025, 10:31 AM by
Antti Siltanen

Modulight extensive report: Building a new growth base

Modulight aims to return to a path of profitable growth after difficult years following its listing.

Modulight
Analyst Comment5/13/2025, 9:57 AM by
Antti Siltanen

Trump vs. Big Pharma – Round One

The US presidential administration has initiated measures to lower drug prices. With Monday's executive order, the administration aims to lower drug prices to the level of other developed countries.

OrionHerantis PharmaFaron PharmaceuticalsModulight
Regulatory press release5/2/2025, 12:30 PM

Resolutions of Modulight Corporation’s Annual General Meeting and Inaugural Meeting of the Board of Directors on 2 May 2025

Modulight

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Modulight Q1'25: Heading in the right direction
Research4/28/2025, 11:17 AM by
Antti Siltanen

Modulight Q1'25: Heading in the right direction

Modulight's Q1 continued on the positive path outlined by the financial statement. Revenue exceeded our expectations and the loss was smaller than forecasted due to lower expenses.

Modulight
Regulatory press release4/25/2025, 10:00 AM

Modulight: Revenue Increased and Profitability Improved

Modulight
Modulight Q1'25 preview: Order book and number of care facilities support revenue
Analyst Comment4/23/2025, 5:48 AM by
Antti Siltanen

Modulight Q1'25 preview: Order book and number of care facilities support revenue

In its previous Q4 report, Modulight reported an increase in the order book and the number of hospitals using its products. Based on this message, we expect growing revenue for the quarter.

Modulight
Press release4/17/2025, 11:30 AM

Modulight to publish its interim report for January–March 2025 on April 25, 2025

Modulight
Regulatory press release4/4/2025, 8:15 AM

Notice To Modulight Corporation's Annual General Meeting

Modulight
Regulatory press release3/14/2025, 11:20 AM

Modulight’s Annual Report 2024 Published

Modulight
Analyst Comment2/26/2025, 7:20 AM by
Antti Siltanen

Modulight receives orders for quantum computing

The customer is an American quantum computing company.

Modulight
Regulatory press release2/25/2025, 8:35 AM

Inside Information: Modulight has received purchase orders worth of 0.8 million dollars

Modulight
Modulight Q4'24: Indications of improving outlook
Research2/24/2025, 7:46 AM by
Antti Siltanen

Modulight Q4'24: Indications of improving outlook

Modulight's reported figures were neutral compared to our forecasts; the report showed positive signs of increased order book and an increase in the number of hospitals using the products.

Modulight
Regulatory press release2/22/2025, 4:10 PM

Proposals of the Shareholders’ Nomination Board of Modulight to the Annual General Meeting 2025

Modulight
Regulatory press release2/21/2025, 11:00 AM

Modulight: Strong order intake and cost reductions improved cash flow despite increased R&D investments

Modulight
Modulight Q4'24 preview: We don't expect any major surprises
Analyst Comment2/20/2025, 6:32 AM by
Antti Siltanen

Modulight Q4'24 preview: We don't expect any major surprises

Modulight will publish its Q4 results on Friday, February 21 at 1:00 pm EET. We expect moderately growing revenue from Phase III clinical projects and ophthalmic lasers.

Modulight
Press release2/14/2025, 2:20 PM

Modulight to publish its financial statements bulletin for January–December 2024 on February 21, 2025

Modulight
Regulatory press release12/31/2024, 9:15 AM

Modulight’s financial reporting and Annual General Meeting in 2025

Modulight
Regulatory press release12/30/2024, 2:00 PM

Change in Modulight Corporation’s holding of treasury shares and annulment of option rights

Modulight
Analyst Comment12/20/2024, 6:24 AM by
Antti Siltanen

Modulight receives order worth 0.5 MEUR

Delivery of the order is scheduled for the second half of 2025 and the first half of 2026.

Modulight
Drug development investment: Value creation through M&As and licensing agreements
Article12/19/2024, 11:07 AM by
Antti Siltanen

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron PharmaceuticalsHerantis PharmaOrionModulight
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.